In search of supporters

Article Abstract:

Commercialization of biotechnology innovations involves large sums of money which is raised by the biotechnology and pharmaceutical companies from stock markets. B iotechnology companies that failed to cash in on the recent bullish trends of the stock market will be left seeking funds from alternative sources. The other drawbacks inherent in some of the local companies that would not make them an ideal candidate for investment are also mentioned.

Australia, Financial management, Services information, Drugs, Innovations, Services, Company investment, Investments, Capital market, Capital markets, Investors, Company financing

---

Biota catches a chill

Article Abstract:

Australian biotechnology firm Biota's success in developing the American approved anti-influenza drug, Relenza has failed to stop its own dramatic fall in share prices.

Biota Holdings

---

Similar abstracts:

• Abstracts: Beer war goes upmarket. Beer's hot contest. To be sure, Guinness sticks to a quirky campaign
• Abstracts: No separation anxiety. Mega-mergers take their toll. This go-it-alone team has the big-firm look
• Abstracts: GST creates big demand for advisers. Consultants take stock. The power of passion
• Abstracts: BHP Billiton's double act. BHP without steel is a political time bomb. The other merger
• Abstracts: Hype and high hopes. Bad to worse. Bird flu bonanza

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.